[email protected]   +1 (304) 306-0723

Wet Age-related Macular Degeneration (wAMD)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

$6,500.00$19,500.00

Growth of the Prevalence wet-AMD population specifically in the elderly population will contribute to increasing sales in the wet-AMD therapy market over our forecast period. According to WHO, by 2050, the world’s population aged 60 years and older is expected to total 2 billion. The rise in the number of the elderly population is a major key driver to develop more safe and effective treatment for wet AMD. Thus, a huge increase in the market size of wet AMD is expected in the coming years. An estimated annual growth rate of 4% in the Prevalent wet-AMD population across the major pharmaceutical markets will contribute to increasing wet-AMD therapy sales. In 2019, there were approximately xx million prevalent cases of wet-AMD in the major markets; we expect the number of cases will exceed xx million in 2030 owing to changes in population demographics and increasing aged population
Clear

Description

According to the American Macular Degeneration Foundation, Wet age-related macular degeneration (wet-AMD) develops when abnormal blood vessels (known as choroidal neovascularization or CNV) grow under the retina and macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. Under these circumstances, vision loss may be rapid and severe.

Wet age-related macular degeneration (wet-AMD) Epidemiology

Age-related macular degeneration (AMD) is, by definition, a disease of the retina that affects older individuals. The early stages of the disease, which include early and intermediate AMD and are mostly asymptomatic, progress slowly to the advanced stages of the disease, which can cause severe vision loss. The AMD patient pool could be further divided into early and intermediate AMD and late AMD. Late AMD can be further divided into two types, the wet form (neovascular AMD, nAMD) and the dry form (geographic atrophy, GA).
Due to the paucity of prevalent studies related to wet AMD, patients were derived from cases of late AMD. For the country-level analysis, our analysts have chosen the latest studies for forecasts from 2020-2030. The forecast is based on the population of 40 years and above.
In the United States The total Prevalent population of Wet Age-related Macular Degeneration (wAMD) in the US ranges from 2388k cases in 2017 to 3461k cases by 2030 with CAGR of 3%.
Wet Age-related Macular Degeneration (wAMD) Prevalent Cases
Wet Age-related Macular Degeneration (wAMD) Prevalent Cases

Wet age-related macular degeneration (wet-AMD) Market Forecast

The Wet Age-related Macular Degeneration (wet-AMD) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2017 to $XX billion in 2030, representing 5.2 % annual growth. Primary drivers of this growth will be the current treatments i.e., Lucentis (Roche, NVS), Eylea (REGN, Bayer) and Avastin and additionally the uptake of the novel emerging treatment i.e., Brolucizumab (Novartis), roxadustat (FibroGen/ Astellas Pharma), KSI-301(Kodiak Sciences)), Faricimab (Roche), OPT-302 (Opthea), RGX-314 (Regenxbio), ADVM-022 (Adverum) and GEM103 (Gemini Therapeutics) predominantly in the United States. Despite new drug approvals, we also foresee decline in wAMD market growth due to the onset of biosimilars and cannibalization of existing drugs.
We model a flatter than originally envisaged launch curve for RTH-258 (brolucizumab) to better reflect the competitive environment in this indication, especially as real-life data tells us that injection frequency with existing drugs are in the range of five times per year, i.e. every 2.4 months. The question is, how fast will the pick-up of drugs approved with three-monthly (quarterly) dosing be? Given the changes mentioned above, total assumed revenues for Novartis from its RTH258 is set to increase from USD XX million in 2020 to USD XX bn in 2030. The drug has already been roll-out continued, with approval now in 57 countries and reimbursement achieved in 11 countries, including the US, Germany, Japan and Italy. Beovu received positive reimbursement recommendation by NICE in the UK. Post marketing cases termed as “retinal vasculitis” and/or “retinal vascular occlusion” that may result in severe vision loss, typically associated with intraocular inflammation and the current COVID-19 situation had an unfavorable impact on sales. Novartis has a comprehensive plan, in strong collaboration with leading external global experts to educate the retina community about the positive benefit / risk profile of Beovu.
wet AMD Annual Revenue $M by Therapies - Mellalta Meets
wet AMD Annual Revenue $M by Therapies – Mellalta Meets

Report Highlights

  • Wet age-related macular degeneration (wet-AMD) Current Market Trends
  • Wet age-related macular degeneration (wet-AMD) Current & Forecasted Cases across the G7 Countries
  • Wet age-related macular degeneration (wet-AMD) Market Opportunities And Sales Potential for Agents
  • Wet age-related macular degeneration (wet-AMD) Patient-based Market Forecast to 2030
  • Wet age-related macular degeneration (wet-AMD) Untapped Business Opportunities
  • Wet age-related macular degeneration (wet-AMD) Product Positioning Vis-a-vis Competitors’ Products
  • Wet age-related macular degeneration (wet-AMD) KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Wet Age-related Macular Degeneration (wAMD) Disease Background
    • Wet Age-related Macular Degeneration (wAMD) Definition
    • Symptoms
    • Risk Factor
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in the United States 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in the United States 2020-2030
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in Germany 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in Germany 2020-2030
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in France 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in France 2020-2030
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in Italy 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in Italy 2020-2030
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in Spain 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in Spain 2020-2030
      • Prevalent of Wet Age-related Macular Degeneration (wAMD) in the United Kingdom 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in the United Kingdom 2020-2030
      • Prevalent Cases of Wet Age-related Macular Degeneration (wAMD) in Japan 2020-2030
      • Diagnosed & Treated Cases of Wet Age-related Macular Degeneration (wAMD) in Japan 2020-2030
  • Current Unmet Needs in Wet Age-related Macular Degeneration (wAMD)
  • Current Treatment Paradigm
    • Treatment guidelines for Wet Age-related Macular Degeneration (wAMD)
    • Current Approved Treatments for Wet Age-related Macular Degeneration (wAMD)
    • Marketed Therapies
      • Ranibizumab (Genentech/Novartis)
      • Aflibercept (Bayer/Regeneron Pharmaceuticals/Sanofi)
      • Brolucizumab (Novartis)
  • Emerging Therapies Chapters
    • ADVM-022 (Adverum)
    • CLS-AX (Clearside Biomedical)
    • EYP-1901 (EyePoint Pharmaceuticals)
    • GEM103( Gemini Therapeutics)
    • GB-102 (Graybug Vision)
    • KSI-301 (Kodiak Sciences)
  • Emerging Therapies Chapters
    • OPT-302 (Opthea Limited)
    • RGX-314 (REGENXBIO)
    • Faricimab (Roche)
    • Lucentis PDS (Roche)
    • RBM-007 (Ribomic)
    • ICON-1 (Iconic Therapeutics)
    • AKST4290 (Alkahest)
  • Future Treatment Paradigm
    • Wet Age-related Macular Degeneration (wAMD) Competitor Landscape and Approvals Anticipated
    • Future Treatment Algorithms and Competitor Positioning
    • Key Data Summary for Emerging Treatment
  • Total Market Forecast
    • Key Summary Findings
      • G7 total Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • G7 total Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
  • Market Forecast by Country
    • United States
      • United States Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • France
      • France Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Wet Age-related Macular Degeneration (wAMD) 2020-2030 (USD Million)
      • United States Market for Wet Age-related Macular Degeneration (wAMD) by Therapies 2020-2030 (USD Million)
  • Market Drivers & Barriers
  • Appendix
  • About Mellalta Meets
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going